
Prime Medicine, Inc. (NASDAQ:PRME – Free Report) – Investment analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Prime Medicine in a research note issued to investors on Monday, November 16th. HC Wainwright analyst A. He now expects that the company will earn ($0.99) per share for the year, up from their prior estimate of ($1.11). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Prime Medicine’s Q4 2026 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.22) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.90) EPS, FY2029 earnings at ($0.94) EPS and FY2030 earnings at ($0.80) EPS.
Prime Medicine (NASDAQ:PRME – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. The company had revenue of $4.21 million for the quarter. Prime Medicine had a negative return on equity of 222.88% and a negative net margin of 2,497.56%.
Check Out Our Latest Stock Analysis on PRME
Prime Medicine Stock Down 8.4%
Shares of PRME opened at $3.84 on Wednesday. Prime Medicine has a 12-month low of $2.67 and a 12-month high of $5.91. The business has a 50-day simple moving average of $3.71 and a two-hundred day simple moving average of $3.51.
Institutional Trading of Prime Medicine
Institutional investors have recently modified their holdings of the business. Alphabet Inc. acquired a new position in shares of Prime Medicine in the second quarter worth approximately $61,116,000. BlackRock Inc. bought a new stake in Prime Medicine in the second quarter valued at approximately $35,432,000. Sumitomo Mitsui Trust Group Inc. increased its position in Prime Medicine by 20.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,911,596 shares of the company’s stock valued at $8,895,000 after purchasing an additional 498,612 shares during the period. ADAR1 Capital Management LLC acquired a new stake in Prime Medicine during the 2nd quarter valued at approximately $7,371,000. Finally, Redmile Group LLC acquired a new stake in Prime Medicine during the 1st quarter valued at approximately $5,536,000. Institutional investors own 70.37% of the company’s stock.
Recent Prime Medicine Headlines
These are some of the PRME headlines that stood out recently:
- Positive Sentiment: HC Wainwright improved its loss forecasts, including Q4 2026 EPS to ($0.26) from ($0.32) and full-year 2026 EPS to ($0.99) from ($1.11). It also modestly raised estimates for 2027–2030, indicating expectations for smaller losses than previously projected. Prime Medicine Stock Rating Reaffirmed as Buy by HC Wainwright
- Positive Sentiment: The firm reiterated its Buy rating and $8 target, well above the $3.84 reference price in the supplied background, a bullish analyst view that could bolster the stock. HC Wainwright stock recommendations
About Prime Medicine
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
Read More
- Five stocks we like better than Prime Medicine
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
